Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is an international (Nordic) trial designed to compare the safety and efficacy of active
conventional therapy (ACT) and three biologic treatments (Certolizumab-pegol, Abatacept or
Tocilizumab) in subjects with early rheumatoid arthritis (RA). The global aim of this study
is to assess and compare two alternative de-escalation strategies in patients who achieved
low disease activity during first-line therapy in the NORD-STAR study.